[1]贾小龙,缪 杰.基于药品专利的仿制药研发法律促进机制研究[J].卫生经济研究,2021,38(2):70-72.
　JIA Xiao-long,MIAO Jie.Research on Legal Promotion Mechanism of Generic Drug Research and Development Based on Drug Patent[J].Journal Press of Health Economics Research,2021,38(2):70-72.
点击复制

基于药品专利的仿制药研发法律促进机制研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年2期
页码:
70-72
栏目:
药械管理
出版日期:
2021-01-20

文章信息/Info

Title:
Research on Legal Promotion Mechanism of Generic Drug Research and Development Based on Drug Patent
作者:
贾小龙1; 缪 杰1
1.兰州理工大学法学院，甘肃 兰州 730000
Author(s):
JIA Xiao-long; MIAO Jie
Law School of Lanzhou University of Technology, Lanzhou Gansu 730000,China
关键词:
药品可及性; 仿制药; 首仿独占期; 无效挑战; 强制许可
Keywords:
drug accessibility;  generic drugs;  exclusive period of first imitation;  invalid challenge;  compulsory license
分类号:
R95
文献标志码:
A
摘要:
目前我国仿制药产业发展“大而不强”，面临的主要制度困境是首仿激励不足、研发专利环境不佳。建立仿制药研发法律促进机制，是改善药品可及性的现实选择，是缓解医疗负担的迫切需求，也是建设制药强国的长久之计。应借鉴新药研发专利激励机制的经验，建立仿制药首仿独占期制度，设立仿制药行业协会，完善药品专利强制许可制度，从而在激励新药研发与促进仿制药发展之间实现更好平衡。
Abstract:
At present,the development of generic drug industry in China is"big but not strong".The main institutional dilemmas are the lack of incentive for the first imitation and the poor environment for R & D patents.The establishment of a legal promotion mechanism for generic drug research and development is a realistic choice to improve drug accessibility,an urgent need to alleviate medical burden,and a long-term solution to build a powerful nation of pharmacy.Learning from the experience of the patent incentive mechanism of new drug research and development,it is necessary to establish the first imitation exclusive period system of generic drugs,set up generic drug industry associations, and improve the compulsory licensing system of drug patents,so as to achieve a better balance between encouraging new drug research and development and promoting the development of generic drugs.

参考文献/References:

[1] 丁锦希，耿露，孙晓东，等.创新药物研发激励政策的量化分析[J].科技进步与对策，2011，28（19）：102-107.
[2] 李红梅.推动企业更好满足大众用药需求[N].人民日报，2019-10-29（05）.
[3] 孙占华.中国仿制药的发展现状分析[EB/OL].(2019-05-27)[2020-06-05].http://www.wanhuida.com/content/details_6_1801.html.
[4] 崔芹芹，张贵民.浅谈仿制药一致性评价研发思路[J].全科口腔医学电子杂志，2019，6（28）：25-30.
[5] 国务院办公厅.国务院办公厅关于改革完善仿制药供应保障及使用政策的意见（国办发〔2018〕20号）[EB/OL].(2018-04-03)[2020-06-11].http://www.gov.cn/zhengce/content/2018-04/03/content_527 9546.htm.
[6] 许子晓.药品专利权与公共健康权的冲突和协调[J].知识产权,2011（3）：92-97.
[7] Association for Accessible Medicines. Biosimilars Access & Savings in the U.S. Report[EB/OL].(2019-01-01)[2020-04-25]https://accessiblemeds.org/resources/blog/2019-generic-drug-and-biosimilars-access-savings-us-report.
[8] 余欣盛.加快迈向新药研发大国[N].人民日报海外版，2019-02-20（10）.
[9] 王立.劳动、应得与正义[J].社会科学研究，2016（2）：131-137.

相似文献/References:

[1]周引德,傅鸿鹏.基层医疗机构药品配备使用情况分析[J].卫生经济研究,2016,(05):38.
[2]李 勇,赵梦蕊,马爱霞,等.我国仿制药一致性评价对药品短缺的影响分析[J].卫生经济研究,2017,(05):47.
[3]殷 婷,汤少梁.基于消费者剩余理论的患者药品福利研究[J].卫生经济研究,2019,(02):13.
　YIN Ting,TANG Shao-liang.Research on Patient Drug Welfare Based on Consumer Surplus Theory[J].Journal Press of Health Economics Research,2019,(2):13.
[4]周菁菁,谈在祥.我国药品带量采购政策实施效果研究——以S医院为例[J].卫生经济研究,2021,38(10):52.
　ZHOU Jing-jing,TAN Zai-xiang.Research on the Implementation Effect of Drug Volume Purchasing Policy in China——Taking S Hospital as an Example[J].Journal Press of Health Economics Research,2021,38(2):52.

更新日期/Last Update: 2021-01-27